Door to the cell for COVID-19 opened, leading way to therapies

doi:10.1038/s41392-020-00215-6

Comment

. 2020 Jun 26;5(1):104.

doi: 10.1038/s41392-020-00215-6.

Door to the cell for COVID-19 opened, leading way to therapies

Zhiwei Huang¹, Jijie Chai²

Affiliations

¹ Center for Life Sciences, School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China. huangzhiwei@hit.edu.cn.
² School of Life Sciences, Tsinghua University, Beijing, 100084, China. chaijj@tsinghua.edu.cn.

PMID: 32591496
PMCID: PMC7317891
DOI: 10.1038/s41392-020-00215-6

Comment

Door to the cell for COVID-19 opened, leading way to therapies

Zhiwei Huang et al. Signal Transduct Target Ther. 2020.

. 2020 Jun 26;5(1):104.

doi: 10.1038/s41392-020-00215-6.

Authors

Zhiwei Huang¹, Jijie Chai²

Affiliations

¹ Center for Life Sciences, School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150080, China. huangzhiwei@hit.edu.cn.
² School of Life Sciences, Tsinghua University, Beijing, 100084, China. chaijj@tsinghua.edu.cn.

PMID: 32591496
PMCID: PMC7317891
DOI: 10.1038/s41392-020-00215-6

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

**Fig. 1**
Structural superposition of SARS-CoV-2 and SARS-CoV RBMs binding to ACE2 receptor. Structural alignment of the SARS-CoV-2 RBD/ACE2 (cyan) and SARS-CoV RBD/ACE2 (pink) complexes (left). The RBM of SARS-CoV-2 and SARS-CoV is shown in yellow and purple, respectively. The remaining portion of the two RBDs is shown in gray. The PDB codes for SARS-CoV-2 RBM/ACE2 and SARS-CoV RBM/ACE2 are 6M0J and 2AJF, respectively. The interface of SARS-CoV-2 RBD and ACE2 receptor is shown in surface view (right). RBD and ACE2 are colored in yellow and cyan, respectively

See this image and copyright information in PMC

Comment on

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. Lan J, et al. Nature. 2020 May;581(7807):215-220. doi: 10.1038/s41586-020-2180-5. Epub 2020 Mar 30. Nature. 2020. PMID: 32225176

Cited by

Development of a SARS-CoV-2 neutralization assay based on a pseudotyped virus using a HIV system.
Liang Z, Tong J, Wu X, Liu S, Wu J, Yu Y, Zhang L, Zhao C, Lu Q, Nie J, Huang W, Wang Y. Liang Z, et al. MedComm (2020). 2024 Mar 22;5(4):e517. doi: 10.1002/mco2.517. eCollection 2024 Apr. MedComm (2020). 2024. PMID: 38525106 Free PMC article.
Host Defence Peptides: A Potent Alternative to Combat Antimicrobial Resistance in the Era of the COVID-19 Pandemic.
Ali W, Elsahn A, Ting DSJ, Dua HS, Mohammed I. Ali W, et al. Antibiotics (Basel). 2022 Apr 1;11(4):475. doi: 10.3390/antibiotics11040475. Antibiotics (Basel). 2022. PMID: 35453226 Free PMC article. Review.
Discovery and characterization of high-affinity, potent SARS-CoV-2 neutralizing antibodies via single B cell screening.
Schardt JS, Pornnoppadol G, Desai AA, Park KS, Zupancic JM, Makowski EK, Smith MD, Chen H, Garcia de Mattos Barbosa M, Cascalho M, Lanigan TM, Moon JJ, Tessier PM. Schardt JS, et al. Sci Rep. 2021 Oct 20;11(1):20738. doi: 10.1038/s41598-021-99401-x. Sci Rep. 2021. PMID: 34671080 Free PMC article.
Will Auranofin Become a Golden New Treatment Against COVID-19?
Sonzogni-Desautels K, Ndao M. Sonzogni-Desautels K, et al. Front Immunol. 2021 Sep 22;12:683694. doi: 10.3389/fimmu.2021.683694. eCollection 2021. Front Immunol. 2021. PMID: 34630379 Free PMC article. Review.
PRAK-03202: A triple antigen virus-like particle vaccine candidate against SARS CoV-2.
Mazumder S, Rastogi R, Undale A, Arora K, Arora NM, Pratim B, Kumar D, Joseph A, Mali B, Arya VB, Kalyanaraman S, Mukherjee A, Gupta A, Potdar S, Roy SS, Parashar D, Paliwal J, Singh SK, Naqvi A, Srivastava A, Singh MK, Kumar D, Bansal S, Rautray S, Saini M, Jain K, Gupta R, Kundu PK. Mazumder S, et al. Heliyon. 2021 Oct;7(10):e08124. doi: 10.1016/j.heliyon.2021.e08124. Epub 2021 Oct 4. Heliyon. 2021. PMID: 34632131 Free PMC article.

See all "Cited by" articles

References

1. Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature10.1038/s41586-020-2180-5 (2020). - PubMed
1. Li F. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 2016;3:237–261. doi: 10.1146/annurev-virology-110615-042301. - DOI - PMC - PubMed
1. Li W, et al. Angiotensin-converting enzyme 2 is afunctional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145. - DOI - PMC - PubMed
1. Wrapp D, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. doi: 10.1126/science.abb2507. - DOI - PMC - PubMed
1. Tian X, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect. 2020;9:382–385. doi: 10.1080/22221751.2020.1729069. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources

[1] Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature10.1038/s41586-020-2180-5 (2020). - PubMed

[2] Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature10.1038/s41586-020-2180-5 (2020). - PubMed

[3] Li F. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 2016;3:237–261. doi: 10.1146/annurev-virology-110615-042301. - DOI - PMC - PubMed

[4] Li F. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 2016;3:237–261. doi: 10.1146/annurev-virology-110615-042301. - DOI - PMC - PubMed

[5] Li W, et al. Angiotensin-converting enzyme 2 is afunctional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145. - DOI - PMC - PubMed

[6] Li W, et al. Angiotensin-converting enzyme 2 is afunctional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145. - DOI - PMC - PubMed

[7] Wrapp D, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. doi: 10.1126/science.abb2507. - DOI - PMC - PubMed

[8] Wrapp D, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. doi: 10.1126/science.abb2507. - DOI - PMC - PubMed

[9] Tian X, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect. 2020;9:382–385. doi: 10.1080/22221751.2020.1729069. - DOI - PMC - PubMed

[10] Tian X, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect. 2020;9:382–385. doi: 10.1080/22221751.2020.1729069. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Door to the cell for COVID-19 opened, leading way to therapies

Affiliations

Door to the cell for COVID-19 opened, leading way to therapies

Authors

Affiliations

Conflict of interest statement

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Conflict of interest statement

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources